Up next

The Supply Lines: Which Companies are Making the News?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms). Which companies are making the news?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging. Which companies are making the news?

Companies making news at DCAT Week 2023 
The Drug, Chemical & Associated Technologies Association (DCAT) held its flagship event, DCAT Week, from March 19 to March 23, 2023, where bio/pharma companies and suppliers convened in New York for high-level business meetings, education programs featuring thought leaders, and networking events. With executives from the bio/pharma industry assembled, DCAT Member Companies took the opportunity to highlight recent news from across the bio/pharmaceutical manufacturing value chain.  

In the March 31, 2023, issue of DCAT Value Chain Insights, we featured companies taking to the podium at the DCAT Member Company Announcement Forum, where senior executives highlighted major news from their companies. Participating in the Forum were: Samsung Biologics, WuXi STA, Bachem, Siegfried, WuXi Biologics, Lonza, Catalent, Thermo Fisher Scientific, Flamma, Porton Pharma, BSP Pharmaceuticals, Granules, Meridian Medical Technologies/Kindeva Drug Delivery, and Incog BioPharma Services. See story, Executives Highlight Expansion Plans at the DCAT Member Company Announcement Forum for a roundup of their news announcements.  

In this issue, DCAT Value Chain Insights highlights other companies making the news in chemical/chemical API manufacturing, biologics manufacturing, formulation development and drug-product manufacturing, end-to-end manufacturing (both drug substances and drug products), and packaging. 

See related stories and the companies making the news below: 

From DCAT Week 2023: Supplier News: Chemicals/Chemical API Manufacturing featuring news from PharmaBlock, Seqens, Polpharma API, Cambrex, Actylis, Avantor, Univar, Procos, Maithri Drugs, Dr. Reddy’s Laboratories, Jubilant Biosys, C2 Pharma, and ChemCon. 

From DCAT Week 2023: Supplier News: Biologics Manufacturing featuring news from BioVectra, Scorpius BioManufacturing, Avid Bioservices, IDT Biologika, Landmark Bio, and Mabion. 

From DCAT Week 2023: Supplier News: Formulation Development/Drug Product Manufacturing featuring news from Evonik, Carbogen Amcis, Vetter, Nanoform, Mikart, Ascendia Pharmaceuticals, Bushu Pharma, and Lifecore Biomedical. 

From DCAT Week 2023: Supplier News: End-to-End (Drug Substance and Drug Product) Mfg with news from CordenPharma and BioDuro Sundia.  

From DCAT Week 2023: Supplier News: Packaging featuring news from PCI Pharma Services, Bormioli, and Tedor Pharma Services. 

Recent Feature Articles

Future-Proofing the Pharma Customer & Supplier Relationship

By
The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

AI: The State of the State in Supply Management 

By
AI and digitalization hold great potential in transforming business functions, but where do they really stand in supply management? An executive panel at DCAT Week will share their perspectives on how AI may transform how pharma companies and their suppliers do business.

What’s in Store for Pharma in 2026 & Beyond?

By
Evolving tariff/trade policy, US drug pricing reforms, and a changing global landscape are contributing to an uncertain environment. A DCAT Week education program, featuring experts from IQVIA, will provide in-depth insights on pharma industry performance. 

Manufacturing Outlook: A Pharma & CDMO View

By
The wave of US pharmaceutical manufacturing investments has garnered the headlines, but are geographic capacity shifts really in the making? A DCAT Week education program will provide expert analysis, including on the all-important, “make-versus-buy” decision.